Publications by authors named "C R Nicolay"
Article Synopsis
- This study examined the baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and assessed how the medication tirzepatide influenced their glycemic control, body weight, and cardiometabolic health.
- It compared 3,792 participants with early-onset T2D to those with later-onset, revealing that early-onset individuals were generally younger, had longer diabetes durations, and exhibited worse metabolic health indicators at the start.
- After 40 weeks of treatment with tirzepatide, both groups showed similar improvements in key health metrics like HbA1c, body weight, waist circumference, and lipid levels, indicating the drug's effectiveness across different onset ages.
Objective: This post hoc analysis assessed change from baseline to week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3 trial) and glargine (SURPASS-4 trial) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting serum glucose (FSG) and postprandial glucose (PPG) values.
Research Design And Methods: Participant subgroups with low FSG/low PPG, low FSG/high PPG, high FSG/low PPG, and high FSG/high PPG were defined according to the median values of these measures.
Results: All tirzepatide doses and basal insulins were associated with decreased HbA1c, FSG, and PPG values from baseline to week 52 in all subgroups (P < 0.
Objective: Dulaglutide (DU) 1.5 mg was associated with improved composite renal outcomes that included new-onset macroalbuminuria in people with type 2 diabetes with previous cardiovascular disease or cardiovascular risk factors in the REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial. This exploratory post hoc analysis evaluated kidney function-related outcomes, excluding the new-onset macroalbuminuria component, among the REWIND participants.
View Article and Find Full Text PDFRelationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme.
Diabetes Obes Metab
September 2023
Aim: To assess the relationship between HbA1c and body weight reductions with tirzepatide treatment (5, 10 or 15 mg).
Materials And Methods: HbA1c and body weight data at 40 weeks (SURPASS-1, -2 and -5) and 52 weeks (SURPASS-3 and -4) were analysed by trial.
Results: Across the SURPASS clinical trials, HbA1c reductions from baseline were observed in 96%-99%, 98%-99% and 94%-99% of participants treated with tirzepatide 5, 10 and 15 mg, respectively.
Background: In clinical practice, anthropometric measures other than BMI are rarely assessed yet may be more predictive of cardiovascular (CV) risk. We analyzed the placebo group of the REWIND CV Outcomes Trial to compare several anthropometric measures as baseline risk factors for cardiovascular disease (CVD)-related outcomes in participants with type 2 diabetes (T2D).
Methods: Data from the REWIND trial placebo group (N = 4952) were analyzed.